Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis | NobleBlocks
Public
Safety, efficacy, and drug survival of the infliximab biosimilar CT‐P13 in post‐marketing surveillance of Japanese patients with psoriasis
N
Shared by NobleBlocks on Jul 7, 2022 • 12:00 AM UTC
